News
-
-
-
COMMUNIQUÉ DE PRESSE
Fondazione Telethon Announces FDA approval of Waskyra™ (etuvetidigene autotemcel), a Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome
Fondazione Telethon announces FDA approval of Waskyra gene therapy for Wiskott-Aldrich Syndrome, offering new hope for patients with rare immunodeficiency. Major achievement in rare disease treatment -
-
-
COMMUNIQUÉ DE PRESSE
Fondazione Telethon announces CHMP positive opinion for Waskyra™, a gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS)
Fondazione Telethon receives CHMP positive opinion for Waskyra™ gene therapy treating Wiskott-Aldrich syndrome, advancing rare disease research and patient care
